SHIFT AI Newsroom · GLOBAL
Tirzepatide and SGLT2 Inhibitors Show Promise for Heart Failure and Obesity
Research suggests a new therapeutic era for heart failure with preserved ejection fraction and obesity, but more evidence is needed
Research published in Europe PMC suggests that Tirzepatide and SGLT2 Inhibitors may be effective for heart failure with preserved ejection fraction and obesity. However, more evidence is needed to fully understand its potential.
What this means in the UK
This research may have implications for the treatment of heart failure and obesity in the UK, but further study is required to fully understand its potential
Known facts
- Tirzepatide and SGLT2 Inhibitors may be effective for heart failure with preserved ejection fraction and obesity